Global Alliance for TB Drug Development (TB Alliance)

The Global Alliance for TB Drug Development (TB Alliance) was established in 2000 as a not-for-profit product development partnership to lead the search for new TB regimens and catalyze global efforts for new TB regimens that can bring hope, and health, to millions. TB Alliance aims to develop a novel treatment regimen for drug sensitive pulmonary TB to shorten the treatment duration from 6 to 4 months.

Global Alliance for TB Drug Development (TB Alliance)

The Global Alliance for TB Drug Development (TB Alliance), established in 2000, brings together industry, NGOs, governments, foundations and more than 30 partners around the world to accelerate the discovery and development of cost-effective new medicines. The TB Alliance draws on the best practices and resources of the public and private sectors to accelerate the discovery and development of cost-effective new anti-TB medicines, which should shorten or simplify treatment, provide a more effective treatment of multidrug-resistant TB and improve treatment of latent TB infection.

TB Alliance is a product development partnership (PDP), working to develop new, simpler, faster-acting TB drug regimens. The current six-month standard treatment period for TB is based on four medicines that were discovered over 40 years ago. Medicines must be taken for 6 to 8 months, frequently under the direct supervision of healthcare professionals as Directly Observed Therapy– short course (DOTS). The alliance aims to reduce TB treatment regimen that should help improve patient compliance, reduce treatment failure rates and decrease the TB-related health costs in endemic disease countries.

The partnership functions as a virtual R&D organization. By outsourcing medicine research and development projects, medicine compounds are moved along the development line to achieve regulatory approval and bring them to market at affordable prices for those countries experiencing the highest burden from TB. TB Alliance activities in low and middle income countries include clinical trials in Kenya, South Africa and Zambia and non-clinical or preclinical work in China and India.

Forging global partnerships, the TB Alliance has partnered with some of the world's leading drug developers to jointly manage TB drug discovery portfolios consisting of multiple TB drug discovery programs. This approach aligns target product profiles, makes efficient use of resources, and leverages the expertise and contributions of each partner to have a significant impact on the global discovery portfolio. The TB Alliance jointly manages TB drug discovery portfolios with AstraZeneca and GlaxoSmithKline.


  • Bill & Melinda Gates Foundation (B&MGF)

    United States | Staff size: 1001-5000
    Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive...
  • Rockefeller Foundation

    United States | Staff size: 101-250

    The Rockefeller Foundation supports work that expands opportunity and strengthens resilience to social, economic, health and environmental challenges—affirming its pioneering philanthropic...

  • United States Agency for International Development (USAID)

    Funding Agencies
    United States | Staff size: Unknown

    USAID is the lead U.S. Government agency that works to end extreme global poverty and enable resilient, democratic societies to realize their potential.

    U.S. foreign assistance has...

  • Department of Foreign Affairs and Trade (IRISH AID) - Ireland

    United States | Staff size: 251-500

    Irish Aid is the Irish Government’s programme for overseas development. The programme is managed by the Development Co-operation Division of the Department of Foreign Affairs and Trade....

  • Ministry of Foreign Affairs (MFA) - The Netherlands

    Funding Agencies
    Netherlands | Staff size: Unknown

    The Ministry of Foreign Affairs promotes the interests of the Kingdom abroad. The Ministry coordinates and carries out Dutch foreign policy at its headquarters in The Hague and through its...

  • Department for International Development (DFID) - United Kingdom

    Funding Agencies
    United Kingdom | Staff size: 1001-5000

    The Department for International Development (DFID) leads the UK’s work to end extreme poverty. DFID is tackling the global challenges of time including poverty and disease, mass...

  • AstraZeneca

    Goods Supplier
    United States | Staff size: 10,000+

    AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company with the primary focus to discover, develop and commercialize prescription medicines for six important areas of...

  • Bayer HealthCare Pharmacuticals

    Institute, Goods Supplier
    United States | Staff size: 10,000+

    Bayer HealthCare Pharmaceuticals is the pharmaceutical division of Bayer HealthCare AG. It markets products in more than 100 countries and in 2011 the company generated sales of almost...

  • GlaxoSmithKline (GSK)

    Goods Supplier
    United Kingdom | Staff size: 10,000+

    We are a science-led global healthcare company that researches and develops a broad range of innovative medicines and brands. Our products are used by millions of people around the world,...

  • Novartis AG

    Goods Supplier
    Switzerland | Staff size: 10,000+

    Novartis AG, was incorporated on 1996, provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of...

More Resources

Key Information

  • Start Date 2000
ValueUSD 450 Million